Amocerebral Plus
Generic Name
Cinnarizine, Dimenhydrinate
Central Nervous System
Active Ingredients
Cinnarizine....................20 mg
Dimenhydrinate..............40 mg
Lactose monohydrate aricel ph200, povidone k30, crocarmellose sodium, sodium stearyl fumarate
For the treatment of vertigo symptoms
Due to the calcium antagonistic properties fo cinnarizine, it acts mainly as a vestibular sedative through inhibition of the calcium influx into the vestibular sensory cells. Cinnarizine thus acts predominantly on the peripheral vestibular system.
Dimenhydrinate acts as an antihistamine with anticholinergic (antimuscarinic) properties, exerting parasympatholytic and centrally depressant effects. The substance exhibits antiemetic and antiverigious effects through influencing the chemoreceptor trigger zone in the region of the 4th ventricle. Dimenhydrinate thus acts predominantly on the central vestibular system.
Both cinnarizine and dimenhydrinate are known to be effective in the treatment of vertigo.

Absortion and Distribution
Dimehydrinate and cinnarizine are rapidly asborbed from the gastrointestinal tract.
Maximum plasma concentration (Cmax) of cinnarizine and dimenhydrinate are reached in humans within 2-4 hours. The plasma elimination half-lives of both substances range from 4-5 hours, when given either alone or as the combination product.
Cinnarizine and dimenhydrinate are extensively metabolised inthe liver.
Cinnarizine is mainly eliminated via the feces (40-60%) and to a lower extent also in urine, mainly in the form of metabolites conjugated with glucuronic acid. The major route of elimination of dimenhydrinate is in the urine, mainly in the form of metabolites.
Treatment of vertigo symptoms of various origins.
Amocerebral Plus is contraindicated in patients with:
  • Known hypersensitivity to cinnarizine and dimenhydrinate.
  • Severe hepatic impairmen.
  • Severe renal impairment (creatinine clearance 25 ml/min).
  • Closed-angle glaucoma, convulsions, suspicion of raised intracranial pressure, alcohol abuse or urine retention due to urethroprostatic disorders.
Drug Interactions
Amocerebral Plus may enhance the sedative effect of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, tricyclic antidepressants, sedatives and tranquilizers.
The side effects of anticholinergic substances such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of antihistamines.
Monoamine-oxiase inhibitors may enhance the antimuscarinic effects of antihistamines.
Side Effects/Adverse Effects
The most frequently occcuring side effects associated with Amocerebral Plus include drowsiness, triedness, faigue and daze. These reactions are usually mild an disappear within a few days if treatment is continued.
The following side effects have also been reported:
1) Immune System:
  • Rare: Hypersensitivity reactions.

2) Nervous System:

  • Common: Headache.
  • Uncommon: Paraesthesia, amnesia, tinnitus, tremor, nervousness, and convulsions.

3) Eye Disorders:

  • Rare: Visual disorders.

4) Gastrointestinal Disorders:

  • Common: Dry mouth, abdominal pain.
  • Uncommon: Dyspepsia, nausea and diarrhea.
Pregnancy & Lactation
Safety and effectiveness of Amocererbral Plus in pregnancy and lactation have not yet been established. Use only under supervision of physician.
Dosage & Administration
The following dosage is generally recommended:
  • Adults and Elderly: 1 tablet three times daily, to be taken with some liquid after meals.
  • Children: Not recommended for use in children and patients under 18 years of age.
In general, the duration of treatment should not exceed four weeks, though it is up to the physician to decide if extension of treatment is required.
Amocerebral Plus may cause drowsiness, especially at the start of treatment; affected patients should not drive or operate machinery.
Amocerebral Plus does not reduce blood pressure significantly, however, it should be used with caution in hypotensive patients.
Amocerebral Plus should be taken after meals to minimize gastric irritation.
Amocerebral Plus should be used with caution in patients with conditions that might be aggravated by anticholinergic therapy, e.g. raised intra-ocular pressure, pyloro-duodenal obstruction, prostatic hypertrophy, hypertension, hyperthyoridism or severe coronary heart disease.
Caution should be exercised when administering Amocerebral Plus to patients with Parkinson's disease.
Store at room temperature, in a dry place.
Box of 3 strips of 10 tablets each.
Amoun Pharmaceuticals
Date Added/Updated
13th March 2013 11:57 am


Share This!

Respected Sites

Need Help?

on-call support